Deepika Jalota - 05 Mar 2026 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Role
Chief Development Officer
Signature
/s/ Robert Ticktin, by power of attorney
Issuer symbol
PMVP
Transactions as of
05 Mar 2026
Net transactions value
$0
Form type
4
Filing time
09 Mar 2026, 16:36:57 UTC
Previous filing
03 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jalota Deepika Chief Development Officer C/O PMV PHARMACEUTICALS, INC., 400 ALEXANDER PARK DRIVE, SUITE 301, PRINCETON /s/ Robert Ticktin, by power of attorney 09 Mar 2026 0001825192

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMVP Employee Stock Option (right to buy) Award +303,310 $0.000000* 303,310 05 Mar 2026 Common Stock 303,310 $1.53 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares subject to the option vest in 48 equal monthly installments beginning on April 5, 2026.